The alterations in liver markers without concomitant elevation of serum total bilirubin levels observed in patients with acute and long COVID-19, and the elevated expression levels of ACE2 in the cholangiocytes, suggest a persistent systemic inflammatory response in these patients [26]. The gene discussed is ACE2; the disease is COVID-19.